Clinical Trials on Preventing Blood Culture Contamination in Ireland

Total 8 results

The Miriam Hospital
National Institutes of Health (NIH); National Center for Complementary and...

Completed

The Gentle Cardiac Rehabilitation Study

Secondary Prevention of Coronary Heart Disease

United States
Boston Scientific Corporation

Completed

Longitudinal Surveillance Study of the 4-SITE Lead/Header System (LSS of 4-SITE)

Primary Prevention of Sudden Cardiac Arrest | Secondary Prevention of Sudden Cardiac Arrest

United States, Canada, Australia
Boehringer Ingelheim

Completed

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Arthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)

Austria, Canada, Czechia, Finland, Netherlands, Sweden
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Completed

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

Prevention & Control

Belgium, Finland, France, China, United States, Colombia, Ireland, Philippines, Japan, Hungary, Canada, Germany, Australia, Chile, Czechia, Korea, Republic of, Malaysia, Brazil, Denmark, Israel, Russian Federation, South Africa, Ecu... and more
Novartis Pharmaceuticals

Recruiting

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Primary Prevention of Atherosclerotic Cardiovascular Disease

United States, China, Italy, Spain, France, Netherlands, Poland, Switzerland, Taiwan, Greece, Thailand, Brazil, India, Hungary, Latvia, Mexico, Israel, Malaysia, Turkey, Argentina, Singapore, Australia, Belgium, Bulgaria, Denmark, Croatia, South... and more
Boehringer Ingelheim

Completed

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Stroke | Secondary Prevention

Korea, Republic of, United States, Spain, Canada, Germany, Taiwan, Belgium, Australia, Hong Kong, India, Singapore, Thailand, Greece, Italy, Japan, China, Turkey, Russian Federation, Serbia, Switzerland, Israel, South Africa, Malaysia, Fran... and more
Bayer

Terminated

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke (OCEANIC-AF)

Atrial Fibrillation | Prevention of Stroke or Systemic Embolism

Canada, United States, Israel, Korea, Republic of, China, Taiwan, Belgium, Australia, Singapore, Malaysia, Slovakia, United Kingdom, Czechia, Latvia, Japan, Brazil, Lithuania, Germany, France, Sweden, Turkey, Switzerland, Estonia, Bul... and more
Bayer

Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic Attack

United States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, France, Slovakia, Austria, Czechi... and more

Clinical Trials on Preventing Blood Culture Contamination in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations